Genetics, transcriptomics, and proteomics of Alzheimer's disease

Andreas Papassotiropoulos, Michael Fountoulakis, Travis Dunckley, Dietrich A. Stephan, Eric M. Reiman

Research output: Contribution to journalReview article

72 Citations (Scopus)

Abstract

Objective: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. Data sources: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. Data synthesis: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, β-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. Conclusions: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.

Original languageEnglish (US)
Pages (from-to)652-670
Number of pages19
JournalJournal of Clinical Psychiatry
Volume67
Issue number4
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Proteomics
Alzheimer Disease
Amyloid beta-Protein Precursor
Amyloid
Presenilin-2
Presenilin-1
Information Storage and Retrieval
Population Genetics
Lipid Metabolism
MEDLINE
Proteolysis
Cerebrospinal Fluid
Early Diagnosis
Proteins
Oxidative Stress
Phosphorylation
Gene Expression
Mutation
Brain
Genes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Papassotiropoulos, A., Fountoulakis, M., Dunckley, T., Stephan, D. A., & Reiman, E. M. (2006). Genetics, transcriptomics, and proteomics of Alzheimer's disease. Journal of Clinical Psychiatry, 67(4), 652-670. https://doi.org/10.4088/JCP.v67n0418

Genetics, transcriptomics, and proteomics of Alzheimer's disease. / Papassotiropoulos, Andreas; Fountoulakis, Michael; Dunckley, Travis; Stephan, Dietrich A.; Reiman, Eric M.

In: Journal of Clinical Psychiatry, Vol. 67, No. 4, 01.01.2006, p. 652-670.

Research output: Contribution to journalReview article

Papassotiropoulos, A, Fountoulakis, M, Dunckley, T, Stephan, DA & Reiman, EM 2006, 'Genetics, transcriptomics, and proteomics of Alzheimer's disease', Journal of Clinical Psychiatry, vol. 67, no. 4, pp. 652-670. https://doi.org/10.4088/JCP.v67n0418
Papassotiropoulos, Andreas ; Fountoulakis, Michael ; Dunckley, Travis ; Stephan, Dietrich A. ; Reiman, Eric M. / Genetics, transcriptomics, and proteomics of Alzheimer's disease. In: Journal of Clinical Psychiatry. 2006 ; Vol. 67, No. 4. pp. 652-670.
@article{2ac300a94dba48638264957982911440,
title = "Genetics, transcriptomics, and proteomics of Alzheimer's disease",
abstract = "Objective: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. Data sources: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. Data synthesis: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, β-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. Conclusions: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.",
author = "Andreas Papassotiropoulos and Michael Fountoulakis and Travis Dunckley and Stephan, {Dietrich A.} and Reiman, {Eric M.}",
year = "2006",
month = "1",
day = "1",
doi = "10.4088/JCP.v67n0418",
language = "English (US)",
volume = "67",
pages = "652--670",
journal = "The Journal of clinical psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Genetics, transcriptomics, and proteomics of Alzheimer's disease

AU - Papassotiropoulos, Andreas

AU - Fountoulakis, Michael

AU - Dunckley, Travis

AU - Stephan, Dietrich A.

AU - Reiman, Eric M.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Objective: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. Data sources: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. Data synthesis: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, β-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. Conclusions: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.

AB - Objective: To provide an updated overview of the methods used in genetic, transcriptomic, and proteomic studies in Alzheimer's disease and to demonstrate the importance of those methods for the improvement of the current diagnostic and therapeutic possibilities. Data sources: MEDLINE-based search of 233 peer-reviewed articles published between 1975 and 2006. Data synthesis: Alzheimer's disease is a genetically heterogeneous disorder. Rare mutations in the amyloid precursor protein, presenilin 1, and presenilin 2 genes have shown the importance of the amyloid metabolism for its development. In addition, converging evidence from population-based genetic studies, gene expression studies, and protein profile studies in the brain and in the cerebrospinal fluid suggest the existence of several pathogenetic pathways such as amyloid precursor protein processing, β-amyloid degradation, tau phosphorylation, proteolysis, protein misfolding, neuroinflammation, oxidative stress, and lipid metabolism. Conclusions: The development of high-throughput genotyping methods and of elaborated statistical analyses will contribute to the identification of genetic risk profiles related to the development and course of this devastating disease. The integration of knowledge derived from genetic, transcriptomic, and proteomic studies will greatly advance our understanding of the causes of Alzheimer's disease, improve our capability of establishing an early diagnosis, help define disease subgroups, and ultimately help to pave the road toward improved and tailored treatments.

UR - http://www.scopus.com/inward/record.url?scp=33646812919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646812919&partnerID=8YFLogxK

U2 - 10.4088/JCP.v67n0418

DO - 10.4088/JCP.v67n0418

M3 - Review article

C2 - 16669732

AN - SCOPUS:33646812919

VL - 67

SP - 652

EP - 670

JO - The Journal of clinical psychiatry

JF - The Journal of clinical psychiatry

SN - 0160-6689

IS - 4

ER -